Human Papillomavirus Infection

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

4100%

+ 26 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

6 programs

GardasilPhase 4

V503Phase 3

ComplianceN/A

Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian MenN/A

+1 more programs

Sharp TherapeuticsPA - Pittsburgh

6 programs

GardasilPhase 41 trial

V503Phase 31 trial

ComplianceN/A1 trial

Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian MenN/A1 trial

+1 more programs

Active Trials

NCT01087164Unknown600Est. Jun 2014

NCT00932009Completed1,933Est. Dec 2009

NCT00572832Completed200Est. Aug 2009

+3 more trials

Guard TherapeuticsSweden - Stockholm

4 programs

Nonavalent HPV study vaccinePhase 3Vaccine1 trial

Recombinant NonavalentPhase 31 trial

Recombinant NonavalentPhase 11 trial

Active Trials

NCT05680454Completed160Est. May 2022

NCT06207175Unknown1,260Est. Jan 2026

NCT05668572Unknown12,000Est. Feb 2023

+1 more trials

Antiva BiosciencesCA - Redwood City

1 program

ABI-2280Phase 1/21 trial

Active Trials

NCT06491446Active Not Recruiting141Est. Jun 2026

BravoVaxChina - Wuhan

1 program

Human papillomavirusPhase 11 trial

Active Trials

NCT05672966Unknown40Est. Oct 2024

ViiV HealthcareNC - Durham

4 programs

Cervarix data collectionN/A

Endocervical samplesN/A

Prevalence-based modelN/A

GSKLONDON, United Kingdom

4 programs

Cervarix data collectionN/A1 trial

Endocervical samplesN/A1 trial

Prevalence-based modelN/A1 trial

Active Trials

NCT01551537Withdrawn0Est. Apr 2014

NCT01158209Completed490Est. Aug 2011

NCT01205412Completed552Est. Nov 2011

+1 more trials

Merck & Co.RAHWAY, NJ

2 programs

Quadrivalent human papillomavirus vaccine on-time administrationN/AVaccine

offer of vaginal self collectionPHASE_2_31 trial

Active Trials

NCT01095198Unknown1,440Est. Jan 2013

Geneva BiotechSwitzerland - Pregny-Chambésy

1 program

HPV testingN/A1 trial

Active Trials

NCT07550010Recruiting1,800Est. Sep 2027

Angeles TherapeuticsCA - Los Angeles

1 program

Parent RemindersN/A1 trial

Active Trials

NCT03726151Unknown17,000Est. Oct 2023

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

Sharp TherapeuticsGardasil

Guard TherapeuticsNonavalent HPV study vaccine

Guard TherapeuticsRecombinant Nonavalent

Sharp TherapeuticsV503

Merck & Co.offer of vaginal self collection

Antiva BiosciencesABI-2280

BravoVaxHuman papillomavirus

Guard TherapeuticsRecombinant Nonavalent

Geneva BiotechHPV testing

Angeles TherapeuticsParent Reminders

GSKCervarix data collection

GSKEndocervical samples

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 43,326 patients across 19 trials

NCT00925288 Sharp TherapeuticsGardasil

Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers

Start: Oct 2009Est. completion: Aug 2011200 patients

Phase 4Completed

NCT06207175 Guard TherapeuticsNonavalent HPV study vaccine

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Start: Nov 2023Est. completion: Jan 20261,260 patients

Phase 3Unknown

NCT05662020 Guard TherapeuticsRecombinant Nonavalent

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Start: Mar 2022Est. completion: Mar 20282,750 patients

Phase 3Active Not Recruiting

NCT05668572 Guard TherapeuticsRecombinant Nonavalent

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Start: Dec 2020Est. completion: Feb 202312,000 patients

Phase 3Unknown

NCT01984697 Sharp TherapeuticsV503

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Start: Dec 2013Est. completion: Jul 20171,518 patients

Phase 3Completed

NCT00988884 Sharp TherapeuticsV503

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Start: Oct 2009Est. completion: Feb 20111,241 patients

Phase 3Completed

NCT01095198 Merck & Co.offer of vaginal self collection

Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)

Start: Apr 2010Est. completion: Jan 20131,440 patients

Phase 2/3Unknown

NCT06491446 Antiva BiosciencesABI-2280

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts

Start: Mar 2024Est. completion: Jun 2026141 patients

Phase 1/2Active Not Recruiting

NCT05672966 BravoVaxHuman papillomavirus

Phase I Clinical Trial of a Candidate HPV Vaccine

Start: Aug 2023Est. completion: Oct 202440 patients

Phase 1Unknown

NCT05680454 Guard TherapeuticsRecombinant Nonavalent

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Start: Sep 2019Est. completion: May 2022160 patients

Phase 1Completed

NCT07550010 Geneva BiotechHPV testing

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Start: Sep 2025Est. completion: Sep 20271,800 patients

N/ARecruiting

NCT03726151 Angeles TherapeuticsParent Reminders

Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs

Start: May 2018Est. completion: Oct 202317,000 patients

N/AUnknown

NCT01551537 GSKCervarix data collection

Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka

Start: Apr 2013Est. completion: Apr 20140

N/AWithdrawn

NCT01205412 GSKEndocervical samples

An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain

Start: Oct 2010Est. completion: Nov 2011552 patients

N/ACompleted

NCT01158209 GSKEndocervical samples

An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt

Start: Oct 2010Est. completion: Aug 2011490 patients

N/ACompleted

NCT01087164 Sharp TherapeuticsCompliance

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

Start: Sep 2010Est. completion: Jun 2014600 patients

N/AUnknown

NCT01702337 GSKPrevalence-based model

Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

Start: Feb 2010Est. completion: Feb 20101 patients

N/ACompleted

NCT00932009 Sharp TherapeuticsPrevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian Men

Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian Men

Start: Mar 2009Est. completion: Dec 20091,933 patients

N/ACompleted

NCT00572832 Sharp TherapeuticsQuadrivalent human papillomavirus vaccine on-time administration

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

Start: Sep 2007Est. completion: Aug 2009200 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 43,326 patients

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.